Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Down 26.3% in November

Vincerx Pharma, Inc. (NASDAQ:VINC) saw a large drop in short interest in November. As of November 15th, there was short interest totalling 600,000 shares, a drop of 26.3% from the October 31st total of 813,800 shares. Based on an average daily volume of 524,300 shares, the short-interest ratio is currently 1.1 days.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Vincerx Pharma by 29.9% during the first quarter. Vanguard Group Inc. now owns 666,995 shares of the company’s stock valued at $3,375,000 after acquiring an additional 153,575 shares during the period. Marshall Wace LLP lifted its position in shares of Vincerx Pharma by 359.1% during the 2nd quarter. Marshall Wace LLP now owns 328,533 shares of the company’s stock worth $266,000 after purchasing an additional 256,967 shares during the last quarter. Finally, Armistice Capital LLC bought a new stake in Vincerx Pharma during the 2nd quarter valued at approximately $1,610,000. 44.02% of the stock is currently owned by institutional investors and hedge funds.

Vincerx Pharma Stock Up 7.9 %

VINC traded up $0.02 on Friday, hitting $0.28. The company had a trading volume of 126,328 shares, compared to its average volume of 668,220. Vincerx Pharma has a 1-year low of $0.24 and a 1-year high of $9.37. The company’s fifty day moving average price is $0.44 and its 200 day moving average price is $0.60.

Analyst Upgrades and Downgrades

Separately, Leerink Partners decreased their price objective on shares of Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th.

About Vincerx Pharma

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.